Detalhe da pesquisa
1.
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
J Neurol Neurosurg Psychiatry;
2024 Mar 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38453478
2.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
J Neurol Neurosurg Psychiatry;
2024 Apr 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38569872
3.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain;
146(11): 4633-4644, 2023 11 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37369086
4.
Risk of secondary progressive multiple sclerosis after early worsening of disability.
J Neurol Neurosurg Psychiatry;
94(12): 984-991, 2023 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37414538
5.
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
J Neurol Neurosurg Psychiatry;
94(1): 23-30, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36171104
6.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry;
94(9): 707-717, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37068931
7.
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Mult Scler;
29(1): 119-129, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35894247
8.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler;
29(7): 875-883, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36851894
9.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler;
29(3): 326-332, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36800908
10.
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol;
30(4): 1014-1024, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36692895
11.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
J Neurol Neurosurg Psychiatry;
93(12): 1330-1337, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36261289
12.
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Mult Scler;
28(6): 958-969, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34623947
13.
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
Mult Scler;
27(3): 465-474, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32530363
14.
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Mult Scler;
26(1): 79-90, 2020 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31397221
15.
Cerebral hypomyelination associated with biallelic variants of FIG4.
Hum Mutat;
40(5): 619-630, 2019 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30740813
16.
Contribution of different relapse phenotypes to disability in multiple sclerosis.
Mult Scler;
23(2): 266-276, 2017 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27055805
17.
Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Intern Med J;
47(2): 194-199, 2017 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27862809
18.
Vaccinations in patients with multiple sclerosis: review and recommendations.
Med J Aust;
214(8): 350-354.e1, 2021 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33866556
19.
Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
Neurology;
102(4): e208059, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38306594
20.
Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic.
BMJ Neurol Open;
6(1): e000667, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38736583